Review ArticleReviewsR
Neoadjuvant Strategy as Initial Treatment in Resectable Pancreatic Cancer: Concrete Evidence of Benefit
FRANCESCA DE FELICE, DANIELA MUSIO, NICOLA RAFFETTO and VINCENZO TOMBOLINI
Anticancer Research September 2014, 34 (9) 4673-4676;
FRANCESCA DE FELICE
1Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
DANIELA MUSIO
1Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
NICOLA RAFFETTO
1Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
VINCENZO TOMBOLINI
1Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
2Spencer-Lorillard Foundation, Rome, Italy
In this issue
Anticancer Research
Vol. 34, Issue 9
September 2014
Neoadjuvant Strategy as Initial Treatment in Resectable Pancreatic Cancer: Concrete Evidence of Benefit
FRANCESCA DE FELICE, DANIELA MUSIO, NICOLA RAFFETTO, VINCENZO TOMBOLINI
Anticancer Research Sep 2014, 34 (9) 4673-4676;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Does Aberrant Right Hepatic Artery Influence the Surgical Short- and Long-term Outcome of Pancreatoduodenectomy?
- Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol
- Predicting Survival After Irradiation of Metastases from Pancreatic Cancer